Lindbrook Capital’s Abeona Therapeutics ABEO Stock Holding History

Lindbrook Capital’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-160	Closed	-$13K	–	1667
2019 Q4	$13K	Buy	+160	New	+$11.3K	﹤0.01%	846

Other funds holding ABEO

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lindbrook Capital's ABEO Position: Q1 2020 in Review

Lindbrook Capital sold out of Abeona Therapeutics (ABEO) in Q1 2020, closing a stake of 160 shares — an estimated $13K sold.

Lindbrook Capital first reported a position in ABEO in Q4 2019 and held it in 1 quarter. The position peaked at $13K in Q4 2019. 80 funds tracked by Wall St. Rank hold ABEO as of Q1 2020.

Lindbrook Capital reported no remaining Abeona Therapeutics position as of Q1 2020 after selling out during the quarter.
Lindbrook Capital sold 160 Abeona Therapeutics shares in Q1 2020, an estimated $13K.
Lindbrook Capital first reported a position in Abeona Therapeutics in Q4 2019 and held it in 1 quarter.
Lindbrook Capital's Abeona Therapeutics position peaked at $13K in Q4 2019.
80 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2020.

Based on Lindbrook Capital's 13F filing for Q1 2020, filed 22 Apr 2020.